HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer

Summary

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment

Description

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  Patritumab deruxtecan

  Patritumab deruxtecan administered via IV infusion

• Biological
  Trastuzumab

  Trastuzumab administered via IV infusion

• Biological
  Trastuzumab Biosimilar

  Trastuzumab biosimilar administered via IV infusion

• Biological
  Pertuzumab

  Pertuzumab administered via IV infusion

• Biological
  Tucatinib

  Tucatinib administered as oral tablets

Locations (17)